Meeder Asset Management’s Regenxbio RGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-51
Closed -$1K – 1731
2022
Q3
$1K Sell
51
-86
-63% -$2.55K ﹤0.01% 2006
2022
Q2
$3K Buy
137
+29
+27% +$725 ﹤0.01% 1823
2022
Q1
$4K Buy
+108
New +$3K ﹤0.01% 1875
2021
Q4
– Sell
-1,443
Closed -$60K – 2079
2021
Q3
$60K Buy
1,443
+1,356
+1,559% +$48.8K ﹤0.01% 1046
2021
Q2
$3K Buy
87
+66
+314% +$2.36K ﹤0.01% 2129
2021
Q1
$1K Hold
21
– – ﹤0.01% 2253
2020
Q4
$1K Sell
21
-8
-28% -$280 ﹤0.01% 1721
2020
Q3
$1K Sell
29
-64
-69% -$2.09K ﹤0.01% 2036
2020
Q2
$3K Sell
93
-399
-81% -$14.9K ﹤0.01% 1688
2020
Q1
$16K Buy
492
+137
+39% +$5.71K ﹤0.01% 1335
2019
Q4
$15K Hold
355
– – ﹤0.01% 1440
2019
Q3
$13K Buy
355
+262
+282% +$10.6K ﹤0.01% 1448
2019
Q2
$5K Sell
93
-2,129
-96% -$106K ﹤0.01% 1676
2019
Q1
$128K Sell
2,222
-356
-14% -$17.6K 0.01% 639
2018
Q4
$109K Buy
2,578
+621
+32% +$36.4K 0.01% 622
2018
Q3
$148K Sell
1,957
-221
-10% -$15.9K 0.01% 552
2018
Q2
$156K Buy
2,178
+2,012
+1,212% +$96.1K 0.01% 542
2018
Q1
$5K Sell
166
-190
-53% -$5.53K ﹤0.01% 1232
2017
Q4
$12K Buy
356
+331
+1,324% +$9.97K ﹤0.01% 1079
2017
Q3
$1K Buy
+25
New +$563 ﹤0.01% 1560
2017
Q2
– Sell
-93
Closed -$2K – 1827
2017
Q1
$2K Buy
+93
New +$1.79K ﹤0.01% 1395

Other funds holding RGNX

Meeder Asset Management's RGNX Position: Q4 2022 in Review

Meeder Asset Management sold out of Regenxbio (RGNX) in Q4 2022, closing a stake of 51 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in RGNX in Q1 2017 and held it in 21 quarters. The position peaked at $156K in Q2 2018. 180 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

  • Meeder Asset Management reported no remaining Regenxbio position as of Q4 2022 after selling out during the quarter.
  • Meeder Asset Management sold 51 Regenxbio shares in Q4 2022, an estimated $1K.
  • Meeder Asset Management first reported a position in Regenxbio in Q1 2017 and held it in 21 quarters.
  • Meeder Asset Management's Regenxbio position peaked at $156K in Q2 2018.
  • 180 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.